Why a third of patients fail biologics


A new study launched in the UK  should give some answers as to why biological treatment does not work in around a third of patients with rheumatoid arthritis. Run by an NIHR Translational Research Partnership in partnership with Janssen the study will explore the molecular pathways that determine whether people with rheumatoid arthritis will benefit ...


Already a member? Login to keep reading


OR
© 2017 the limbic